RT Journal Article
SR Electronic
T1 Fluctuating High Throughput Serological Assay Results in Recurrent Convalescent Plasma Donors
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.25.20219147
DO 10.1101/2020.10.25.20219147
A1 Larry L. Luchsinger
A1 Shiraz Rehmani
A1 Andrew Opalka
A1 Donna Strauss
A1 Christopher D. Hillyer
A1 Patricia Shi
A1 Bruce S. Sachais
YR 2020
UL http://medrxiv.org/content/early/2020/10/27/2020.10.25.20219147.abstract
AB The clinical and scientific communities rely on serology testing to analyze the degree of antibody-mediated immunity afforded to recovered patients from SARS-CoV-2 infection. Neutralizing antibodies present in COVID-19 convalescent plasma (CCP) remains a practical therapy to treat COVID-19 patients requiring hospitalization. However, it remains unclear how long antibody levels persist in CCP donors after recovery. An accurate estimation of antibody kinetics in CCP donors provide an important observation to further define the extent of long-term immunity in recovered patient and simultaneously inform CCP collection processes in efforts to improve CCP dosing and therapeutic outcome. In this study, we analyzed 63 donors and measured antibody levels using two high throughput screening assays (HTSA) designed to detect antibodies targeting the spike protein (S1) and nucleocapsid protein (NP) of SARS-CoV-2 and monitored antibody levels between 2-8 consecutive donations. We show that anti-S1 antibody levels, as measured using the Ortho Total Ig HTSA, increased over time in repeat CCP donors while anti-NP antibody levels, as measured using the Abbott IgG HTSA, were unchanged or decreased over time. When we normalized these data, we found that both the absolute levels of anti-S1 antibodies and the ratio between S1 and NP antibodies tends to increase over time. These data have important implications for the convalescent donation process, patient protection from future infection and characterization of the SARS-CoV-2 immune response.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDonor collection and performance of the HTSA and LFA serological assays was funded through the New York Blood Center and the Rockefeller University.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The New York Blood Center IRB has determined this project does not meet the definition of human subject research under the purview of the IRB according to federal regulations. IRB Reference ID: 1596981-1 IRB Reference Title: COVID19 Convalescent Plasma Serology Testing All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll raw data is available upon request to the corresponding authors.